Canine Adenovirus Type 2, Manhattan, Mlv; Canine Distemper Virus, N-Cdv, Mlv; Ca
36 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
36
Total Reports
5
Deaths Reported
1390.0%
Death Rate
Active Ingredients
Canine Adenovirus Type 2, Manhattan, Mlv; Canine Distemper Virus, N-Cdv, Mlv; Ca
Administration Routes
Subcutaneous
Species Affected
Dog 36
Most Affected Breeds
Retriever - Labrador 5
Chihuahua 4
Terrier - Bull - American Pit 4
Crossbred Canine/dog 3
Boxer (German Boxer) 2
Siberian Husky 2
Saint Bernard Dog 2
Terrier - Yorkshire 1
Shepherd (unspecified) 1
Spitz - German Pomeranian 1
Most Reported Reactions
Lethargy (see also Central nervous system depression in 'Neurological') 15
Vomiting 11
Anaphylactoid reaction 8
Other abnormal test result NOS 6
Elevated liver enzymes 5
Facial swelling (see also 'Skin') 5
Anaphylaxis 4
Anaemia NOS 4
Emesis 4
Anorexia 4
Diarrhoea 4
INEFFECTIVE, ANTIEMETIC 4
Outcome Breakdown
Ongoing
19 (52.8%)
Recovered/Normal
9 (25.0%)
Died
3 (8.3%)
Euthanized
2 (5.6%)
Outcome Unknown
2 (5.6%)
Recovered with Sequela
1 (2.8%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.